GLP1R and obesity due to melanocortin 4 receptor deficiency: GLP1R has recently been implicated as a multimodal receptor involved in cardiometabolic disease and is targeted by several US Food and Drug Administration–approved drugs for the treatment of type 2 diabetes and obesity (30–32).